Home Microbiology Bacterial chemical Teicoplanin

research use only

Teicoplanin Bacterial chemical

Cat.No.S1399

Teicoplanin (Teichomycin,Targocid,MDL-507) is a glycopeptide antibiotic, used to treat serious infections caused by Gram-positive bacteria.
Teicoplanin Bacterial chemical Chemical Structure

Chemical Structure

Molecular Weight: 1709.39

Jump to

Quality Control

Batch: Purity: 99.34%
99.34

Solubility

In vitro
Batch:

Water : 100 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 1709.39 Formula

C77H77N9O31Cl2·R

 Storage (From the date of receipt)
CAS No. 61036-62-2 Download SDF Storage of Stock Solutions

Synonyms Teichomycin,Targocid,MDL-507 Smiles CCCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)OC1C(C(C(C(O1)CO)O)O)NC(=O)C)Cl)CO)O)O

Mechanism of Action

In vitro

Teicoplanin is associated with small increases in the GI colonization by C. albicans. The inhibitory action of this compound on proteoglycan polymerization but not on nucleic acid and protein synthesis indicates that the effect in the wall is due to the accumulation at this level of proteoglycan soluble precursors continuously produced by the cell. It, at a concentration of 1 mg/mL, causes rapid lysis of exponential phase cells of Streptococcus faecalis. This compound inhibits peptidoglycan synthesis in intact cells and in cell-free systems. This chemical-induced lysis is dependent on the growth phase of B. pumilus at the time of addition of the antibiotic. It induces lysis after a longer lag phase with slowly growing Strep. jhecalis CCM 1875 and lysis is not very extensive.

In vivo

Teicoplanin therapy increases the survival rate whereas G-CSF therapy does not in comparison to other groups in neutropenic mice. This compound and G-CSF combination therapy improves survival rate when compared with groups II, III, IV.

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/1830328/
  • [5] https://pubmed.ncbi.nlm.nih.gov/12678538/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03909698 Completed
Kidney Failure Chronic|Antibiotics|Hemodialysis
University Hospital Ghent|University Ghent
 September 15 2016 --
NCT03229135 Completed
Pneumonia Gram-Positive Bacterial
People''s Hospital of Zhengzhou University
 February 1 2015 --
NCT03177369 Completed
Teicoplanin-based Antimicrobial Therapy|Staphylococcus Aureus|Bone and Joint Infection
Hospices Civils de Lyon
 January 2015 --
NCT01324804 Unknown status
Coronary Heart Disease|Surgical Wound Infection
Medical University of Vienna
 November 2010 --
NCT00754273 Completed
Methicillin-resistant Staphylococcal Aureus Pneumonia
University of Kentucky|Pfizer
 September 2008 --

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.